Table 1.
Characteristics of Trials by APAC Leadership and Collaborator Status
| Number of Trials (N = 656) | Lead Authors |
Trial Collaborators |
|||
|---|---|---|---|---|---|
| APAC (n = 52, 7.9%) | Non-APAC (n = 604, 92.1%) | APAC (n = 1,312, 10.1%) | Non-APAC (n = 11,688, 89.9%) | ||
| Disease type | |||||
| Aortic disease | 5 (0.8) | 0 (0) | 5 (100.0) | 0 (0) | 50 (100.0) |
| Arrhythmia | 48 (7.3) | 4 (8.3) | 44 (91.7) | 77 (8.9) | 790 (91.1) |
| CAD | 220 (33.5) | 28 (12.7) | 192 (87.3) | 563 (11.7) | 4,256 (88.3) |
| CeVD | 84 (12.8) | 12 (14.3) | 72 (85.7) | 444 (23.7) | 1,428 (76.3) |
| Critical care/resuscitation | 24 (3.7) | 0 (0) | 24 (100.0) | 21 (4.2) | 482 (95.8) |
| Diabetes | 75 (11.4) | 2 (2.7) | 73 (97.3) | 52 (4.7) | 1,048 (95.3) |
| DVT/PE | 21 (3.2) | 1 (4.8) | 20 (95.2) | 14 (3.8) | 354 (96.2) |
| HF/cardiomyopathy | 62 (9.5) | 0 (0) | 62 (100.0) | 36 (2.7) | 1,291 (97.3) |
| Hypertension | 19 (2.9) | 2 (10.5) | 17 (89.5) | 51 (13.6) | 325 (86.4) |
| Lipid disorders | 24 (3.7) | 2 (8.3) | 22 (91.7) | 17 (4.7) | 342 (95.3) |
| Obesity | 32 (4.9) | 0 (0) | 32 (100.0) | 15 (3.1) | 476 (97.0) |
| PAD | 14 (2.1) | 0 (0) | 14 (100.0) | 3 (1.4) | 211 (98.6) |
| PAH | 2 (0.3) | 0 (0) | 2 (100.0) | 3 (12.0) | 22 (88.0) |
| Pericardial disease | 3 (0.5) | 0 (0) | 3 (100.0) | 0 (0) | 67 (100.0) |
| Valvular heart disease | 23 (3.5) | 1 (4.3) | 22 (95.7) | 16 (2.9) | 546 (97.2) |
| Year of publication | |||||
| 2011 | 51 | 2 (3.9) | 49 (96.1) | 68 (7.3) | 859 (92.7) |
| 2012 | 62 | 2 (3.2) | 60 (96.8) | 35 (3.6) | 939 (96.4) |
| 2013 | 69 | 3 (4.3) | 66 (95.7) | 61 (5.4) | 1,077 (94.6) |
| 2014 | 52 | 5 (9.6) | 47 (90.4) | 70 (6.7) | 968 (93.3) |
| 2015 | 75 | 7 (9.3) | 68 (90.7) | 152 (10.8) | 1,259 (89.2) |
| 2016 | 62 | 5 (8.1) | 57 (91.9) | 92 (7.7) | 1,102 (92.3) |
| 2017 | 64 | 4 (6.3) | 60 (93.8) | 105 (8.1) | 1,195 (91.9) |
| 2018 | 69 | 8 (11.6) | 61 (88.4) | 238 (14.8) | 1,376 (85.3) |
| 2019 | 90 | 6 (6.7) | 84 (93.3) | 210 (10.6) | 1,770 (89.4) |
| 2020 | 62 | 10 (16.1) | 52 (83.9) | 281 (19.7) | 1,143 (80.3) |
| Site location | |||||
| Asia Pacific | 34 | 31 (91.2) | 3 (8.8) | 680 (94.7) | 38 (5.3) |
| Middle East/Africa | 2 | 0 (0) | 2 (100.0) | 0 (0) | 64 (100.0) |
| North America | 147 | 0 (0) | 147 (100.0) | 1 (0.04) | 2,633 (99.9) |
| South America | 5 | 0 (0) | 5 (100.0) | 0 (0) | 140 (100.0) |
| Western/Central Europe | 166 | 0 (0) | 166 (100.0) | 17 (0.5) | 3,225 (99.5) |
| Multiregional | 302 | 21 (7.0) | 281 (93.0) | 614 (9.9) | 5,588 (90.1) |
| Funding | |||||
| Industry | 335 | 18 (5.4) | 317 (94.6) | 430 (6.9) | 5,826 (93.1) |
| Nonindustry | 321 | 34 (10.6) | 287 (89.4) | 882 (13.1) | 5,862 (86.9) |
Values are n (%) unless otherwise indicated.
APAC = Asia-Pacific; CAD = coronary artery disease; CeVD = cerebrovascular disease; DVT = deep venous thrombosis; HF = heart failure; PAD = peripheral artery disease; PAH = pulmonary arterial hypertension; PE = pulmonary embolism.